Results 201 to 210 of about 16,449,484 (363)

Aberrant Cell Cycle Gene Expression in a Transgenic Mouse Model of Alzheimer's Disease. [PDF]

Cells
Lanza M, Scuruchi M, Saitta A, Basilotta R, Aliquò F, Casili G, Esposito E, Copani A, Oddo S, Caccamo A.   +9 more
europepmc   +1 more source

A nonenzymatic dependency on inositol-requiring enzyme 1 controls cancer cell cycle progression and tumor growth

Iratxe Zuazo-Gaztelu, David A. Lawrence, Ioanna Oikonomidi, Scot A. Marsters, Ximo Pechuan-Jorge, Catarina J Gaspar, David Kan, Ehud Segal, Kevin Clark, Maureen H. Beresini, Marie-Gabrielle Braun, Joachim Rudolph, Zora Modrušan, Meena Choi, Wendy Sandoval, Mike Reichelt, David C. DeWitt, Pekka Kujala, Suzanne van Dijk, Judith Klumperman, Avi Ashkenazi   +20 more
openalex   +1 more source

Table ST1 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

, 2023
Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia‐Ribas, Toshihiko Doi, Noboru Yamamoto   +15 more
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

HES1 oscillations are required for cell cycle reentry in oestrogen receptor-positive breast cancer cells. [PDF]

Proc Natl Acad Sci U S A
Cottrell O, Rowntree A, Chopra K, Mackellar E, Noble B, Dixon HL, Healy C, Clarke RB, Papalopulu N.   +8 more
europepmc   +1 more source

Modulation of Protein-Interaction States through the Cell Cycle.

Cell, 2018
Lingyun Dai, T. Zhao, Xavier Bisteau, Wendi Sun, N. Prabhu, Y. Lim, R. Sobota, P. Kaldis, P. Nordlund   +8 more
semanticscholar   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Comprehensive profiling of chromatin occupancy dynamics through the cell cycle. [PDF]

Nucleic Acids Res
Li Y, MacAlpine DM, Hartemink AJ.
europepmc   +1 more source

The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.

Cold Spring Harbor Perspectives in Medicine, 2016
Jiandong Chen
semanticscholar   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source